Medimmune Bets on Pain: Why The Large Molecule Specialist Thinks It Can Win
AstraZeneca PLC has operated Medimmune as an independent R&D subsidiary since 2007, with Centers of Excellence organized around large molecules in targeted therapeutic areas. The company retains small molecule development under the AZ umbrella, leading to what some might refer to as friendly" co-opetition."
You may also be interested in...
Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care
Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.
J&J Wins Nucynta ER Approval, Targets Chronic Pain Market
The company plans a push for the extended release formulation of its opioid medication.
AstraZeneca Rebuilds Its R&D, With Payers In Mind
When Martin Mackay joined AstraZeneca PLC as president, global research & development, from Pfizer Inc. one year ago, one of his objectives was to "put AstraZeneca's R&D back on the map."